- Home
- MRSN vs SRTS Comparison
MRSN vs SRTS Comparison
Compare MRSN & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- SRTS
- Stock Information
- Founded
- MRSN 2001
- SRTS 2010
- Country
- MRSN United States
- SRTS United States
- Employees
- MRSN N/A
- SRTS N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- MRSN Health Care
- SRTS Health Care
- Exchange
- MRSN Nasdaq
- SRTS Nasdaq
- Market Cap
- MRSN 47.1M
- SRTS 52.9M
- IPO Year
- MRSN 2017
- SRTS 2016
- Fundamental
- Price
- MRSN $27.87
- SRTS $4.35
- Analyst Decision
- MRSN Buy
- SRTS Strong Buy
- Analyst Count
- MRSN 5
- SRTS 3
- Target Price
- MRSN $30.38
- SRTS $8.00
- AVG Volume (30 Days)
- MRSN 211.4K
- SRTS 165.9K
- Earning Date
- MRSN 11-14-2025
- SRTS 11-06-2025
- Dividend Yield
- MRSN N/A
- SRTS N/A
- EPS Growth
- MRSN N/A
- SRTS N/A
- EPS
- MRSN N/A
- SRTS N/A
- Revenue
- MRSN $33,180,000.00
- SRTS $35,609,000.00
- Revenue This Year
- MRSN N/A
- SRTS N/A
- Revenue Next Year
- MRSN N/A
- SRTS $47.33
- P/E Ratio
- MRSN N/A
- SRTS N/A
- Revenue Growth
- MRSN N/A
- SRTS N/A
- 52 Week Low
- MRSN $5.21
- SRTS $3.03
- 52 Week High
- MRSN $70.73
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- MRSN 89.87
- SRTS 64.56
- Support Level
- MRSN $7.59
- SRTS $4.11
- Resistance Level
- MRSN $28.07
- SRTS $4.69
- Average True Range (ATR)
- MRSN 0.69
- SRTS 0.36
- MACD
- MRSN 1.80
- SRTS 0.12
- Stochastic Oscillator
- MRSN 99.51
- SRTS 77.78
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.